AMENDMENT UNDER 37 C.F.R. § 1.116

U.S. Application. No.: 10/670,004 Attorney Docket No.: Q77153

AMENDMENTS TO THE SPECIFICATION

Please replace the paragraph at page 4, lines 2-14 with the following amended paragraph:

The liposome of the present invention is characterized to contain, as a membrane component, an active ingredient of a medicament for prophylactic and/or therapeutic treatment of a vascular disease caused by abnormal proliferation of vascular smooth muscle cells. The type of the active ingredient of a medicament for prophylactic and/or therapeutic treatment of a vascular disease caused by abnormal proliferation of vascular smooth muscle cells is not particularly limited. For example, the active ingredient may preferably those can suppress foaming of macrophages. Bebzimidazole Benzimidazole derivatives that strongly suppress foaming of macrophages and have reduced side effect are known, and they can be most preferably used for manufacture of the liposome of the present invention (Japanese Patent Unexamined Publication Nos. 6-48942 and 7-228530. International Patent Publication WO95/21160, Japanese Patent Unexamined Publication Nos. 9-31062 and 9-40669) (Japanese Patent Unexamined Publication No. 6-48942 and its counterpart U.S. Patent No. 5,962,493; Japanese Patent Unexamined Publication No. 7-228530; International Patent Publication WO 95/21160 and its counterpart U.S. Patent No. 5,962,493; Japanese Patent Unexamined Publication Nos. 9-31062 and 9-40669 and their counterparts U.S. Patent Nos. 5,998,456, 6,174,907, and 6,288,236).